Theravance Biopharma TBPH Other Non-Current Liabilities

Other Non-Current Liabilities at other companies

Gyre Therapeutics, Inc.GYRE

$70K-95.1%

Royalty PharmaRPRX

$108.02M-24.6%

United TherapeuticsUTHR

$212M+2.3%

Zevra Therapeutics, Inc.ZVRA

$2.09M-37.1%

Aurinia PharmaceuticalsAUPH

$945K-92.1%

Mirum Pharmaceuticals, Inc.MIRM

$10.92M+20.6%

FAQ

What is Theravance Biopharma's other non-current liabilities?

Theravance Biopharma (TBPH) reported other non-current liabilities of $244K in Q2 2026.

How has Theravance Biopharma's other non-current liabilities changed year-over-year?

Theravance Biopharma's other non-current liabilities decreased by 84.2% year-over-year, from $1.55M to $244K.

What is the long-term trend for Theravance Biopharma's other non-current liabilities?

Over 5 years (2020 to 2025), Theravance Biopharma's other non-current liabilities has grown at a -29.8% compound annual growth rate (CAGR), from $1.83M to $313K.

What does other non-current liabilities mean?

Miscellaneous long-term obligations not classified in specific categories — pension liabilities, environmental remediation, and other long-term accruals.